Some potential pathways include 133-138: increasing the expression of major histocompatibility complex class I antigen on tumor cells, recruiting more antigen-presenting cells, changing the tumor immunosuppressive microenvironment or up-regulating PD-L1 expression on tumor cells, and inducing cytotoxic effects to promote the release of tumor antigens and damage-associated molecular patterns (DAMPs) therefore reactivating the cancer-immune cycle. The gene discussed is CD274; the disease is neoplasm.